We show here that celecoxib, at concentrations near those required for its anti-inflammatory effects, suppresses proliferation and colony formation of imatinib-sensitive and resistant Ph+ cell lines and primary cells, including CD34+ CML cells. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.